美股异动丨礼来盘前续涨超1% 口服药物Orforglipron后期试验达到目标

Group 1 - The core point of the article is that Eli Lilly's oral weight loss drug Orforglipron has successfully met its primary research goals in a late-stage clinical trial for obesity and type 2 diabetes patients, with plans for a global launch next year [1] - In a 72-week study, patients receiving the highest dose of Orforglipron lost an average of 10.5% of their body weight, equating to 22.9 pounds, while the placebo group lost only 2.2 pounds [1] - Including patients who discontinued the medication, the overall weight loss effect of the drug was 9.6% [1] Group 2 - Following the announcement, Eli Lilly's stock rose by 5.85% to close at $736.03, and it continued to increase by 1.49% in pre-market trading, reaching $747.02 [1] - The stock's trading volume was 7.6956 million shares, with a market capitalization of $696.621 billion [1] - The stock has a price-to-earnings ratio of 48.11 and a price-to-book ratio of 38.122, indicating a high valuation relative to earnings and book value [1]